Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial

English version České info

Background:
Few data have described long-term outcomes for infants born to HIV-infected African women taking antiretroviral therapy (ART) in pregnancy. This is particularly true for World Health Organization (WHO)–recommended tenofovir-containing first-line regimens, which are increasingly used and known to cause renal and bone toxicities; concerns have been raised about potential toxicity in babies due to in utero tenofovir exposure.

Methods and Findings:
Pregnancy outcome and maternal/infant ART were collected in Ugandan/Zimbabwean HIV-infected women initiating ART during The Development of AntiRetroviral Therapy in Africa (DART) trial, which compared routine laboratory monitoring (CD4; toxicity) versus clinically driven monitoring. Women were followed 15 January 2003 to 28 September 2009. Infant feeding, clinical status, and biochemistry/haematology results were collected in a separate infant study. Effect of in utero ART exposure on infant growth was analysed using random effects models.

382 pregnancies occurred in 302/1,867 (16%) women (4.4/100 woman-years [95% CI 4.0–4.9]). 226/390 (58%) outcomes were live-births, 27 (7%) stillbirths (≥22 wk), and 137 (35%) terminations/miscarriages (<22 wk). Of 226 live-births, seven (3%) infants died <2 wk from perinatal causes and there were seven (3%) congenital abnormalities, with no effect of in utero tenofovir exposure (p>0.4). Of 219 surviving infants, 182 (83%) enrolled in the follow-up study; median (interquartile range [IQR]) age at last visit was 25 (12–38) months. From mothers' ART, 62/9/111 infants had no/20%–89%/≥90% in utero tenofovir exposure; most were also zidovudine/lamivudine exposed. All 172 infants tested were HIV-negative (ten untested). Only 73/182(40%) infants were breast-fed for median 94 (IQR 75–212) days. Overall, 14 infants died at median (IQR) age 9 (3–23) months, giving 5% 12-month mortality; six of 14 were HIV-uninfected; eight untested infants died of respiratory infection (three), sepsis (two), burns (one), measles (one), unknown (one). During follow-up, no bone fractures were reported to have occurred; 12/368 creatinines and seven out of 305 phosphates were grade one (16) or two (three) in 14 children with no effect of in utero tenofovir (p>0.1). There was no evidence that in utero tenofovir affected growth after 2 years (p = 0.38). Attained height- and weight for age were similar to general (HIV-uninfected) Ugandan populations. Study limitations included relatively small size and lack of randomisation to maternal ART regimens.

Conclusions:
Overall 1-year 5% infant mortality was similar to the 2%–4% post-neonatal mortality observed in this region. No increase in congenital, renal, or growth abnormalities was observed with in utero tenofovir exposure. Although some infants died untested, absence of recorded HIV infection with combination ART in pregnancy is encouraging. Detailed safety of tenofovir for pre-exposure prophylaxis will need confirmation from longer term follow-up of larger numbers of exposed children.

Trial registration:
www.controlled-trials.com ISRCTN13968779

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. PLoS Med 9(5): e32767. doi:10.1371/journal.pmed.1001217
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001217

Souhrn

Trial registration:
www.controlled-trials.com ISRCTN13968779

: Please see later in the article for the Editors' Summary

Zdroje

1. Kesho Bora Study Group 2011 Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11 171 180

2. ShapiroRLHughesMDOgwuAKitchDLockmanS 2010 Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 362 2282 2294

3. World Health Organization 2010 Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach. 2010 revision Geneva WHO

4. World Health Organization 2010 Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Available: http://www.who.int/hiv/pub/2010progressreport/report/en/index.html. Accessed 18 April 2010

5. World Health Organization 2011 Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2011. Available: http://www.who.int/hiv/pub/progress_report2011/en/index.html. Accessed 10 December 2011

6. PARTNERS PrEP study 2011 Pivotal study finds that HIV medications are highly effective as prophylaxis against HIV infection in men and women in Africa Seattle (Washington) International Clinical Research Center (ICRC)

7. GrantRMLamaJRAndersonPLMcMahanVLiuAY 2010 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363 2587 2599

8. Antiretroviral Pregnancy Register 2011 Interim Report 1 January 1989 through 31 January 2011. Available: http://www.apregistry.com/forms/interim_report.pdf. Accessed 24 August 2011

9. FosterCLyallHOlmscheidBPearceGZhangS 2009 Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? HIV Med 10 397 406

10. McCormackSRamjeeGKamaliAReesHCrookAM 2010 PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376 1329 1337

11. MunderiPWilkesHTumukundeDChidzivaENalumenyaR 2009 Pregnancy rates & outcomes among women on triple-drug antiretroviral therapy in the DART trial [Abstract WEPEB261]. In: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 19–22 July 2009; Capetown, South Africa

12. MyerLCarterRJKatyalMToroPEl-SadrWM 2010 Impact of antiretroviral therapy on incidence of pregnancy among HIV-infected women in Sub-Saharan Africa: a cohort study. PLoS Med 7 e1000229 doi:10.1371/journal.pmed.1000229

13. UNAIDS 2008 Total fertility rate. Available: http://data.un.org/Data.aspx?d=SOWC&f=inID%3A127. Accessed 18 January 2011

14. DART Trial Team 2010 Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375 123 131

15. World Health Organization 2006 Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach Geneva WHO

16. DART Trial Team 2008 Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13 6 16

17. BayleyN 1993 Bayley scales of infant development. 2nd edition San Antonio (Texas, US) The Psychological Corporation

18. Division of AIDS (DAIDS) 2004 Table for the grading of the severity of adult and pediatric adverse events (December 2004). Available: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.doc. Accessed 16 April 2012

19. NIH Division and Infectious Diseases (DMID) 2007 Pediatric toxicity tables (November 2007). Available: http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClinRsrch/Documents/dmidpedtox.pdf. Accessed 16 April 2012

20. WHO Child Growth Standards Group 2009 Growth velocity based on weight, length, and head circumference: methods and development Geneva WHO

21. CortinovisIVellaVNdikuNMilaniS 1997 Weight, height and arm circumference of children under 5 in the district of Mbarara, south-west Uganda. Ann Hum Biol 24 557 568

22. ChiBHMwangoAGigantiMMulengaLBTambatamba-ChapulaB 2010 Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr 54 63 70

23. Panel on Antiretroviral Guidelines for Adults and Adolescents 2011 Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 20 January 2011

24. European AIDS Clinical Society 2011 Guidelines for clinical management and treatment of HIV-infected adults in Europe. Version 6. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf. Accessed 16 April 2012

25. CohenMSChenYQMcCauleyMGambleTHosseinipourM 2011 Prevention of HIV-1 infection with early antiretroviral therapy. N Eng J Med 365 493 505

26. Centers for Disease Control and Prevention 2011 Results of FEM-PrEP clinical trial examining pre-exposure prophylaxis (PrEP) for HIV prevention among heterosexual women Atlanta (Georgia) CDC

27. BussmannHWesterCWWesterCNLekokoBOkezieO 2007 Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr 45 269 273

28. RamjeeGKapigaSWeissSPetersonLLeburgC 2008 The value of site preparedness studies for future implementation of phase 2/IIb/III HIV prevention trials: experience from the HPTN 055 study. J Acquir Immune Defic Syndr 47 93 100

29. BenaboudSPruvostACoffiePAEkoueviDKUrienS 2011 Breast milk concentrations of tenofovir and emtricitabine in HIV-1 infected women in Abidjan TEmAA Step 2 (ANRS 12109). Antimicrob Agents Chemother 55 1315 1317

30. HirtDUrienSEkoueviDKReyEArriveE 2009 Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 85 182 189

31. Van RompayKKBrignoloLLMeyerDJJeromeCTararaR 2004 Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48 1469 1487

32. Van RompayKKDurand-GasselinLBrignoloLLRayASAbelK 2008 Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52 3144 3160

33. TarantalAFCastilloAEkertJEBischofbergerNMartinRB 2002 Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 29 207 220

34. CorreaACraganJDKucikJEAlversonCJGilboaSM 2007 Metropolitan Atlanta Congenital Defects Program 40th Anniversary Edition Surveillance Report: Reporting birth defects surveillance data 1968–2003. Birth Defects Res A Clin Mol Teratol 79 65 93. Erratum: 2008;82:41–62

35. TownsendCLCortina-BorjaMPeckhamCSTookeyPA 2007 Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 21 1019 1026

36. KourtisAPSchmidCHJamiesonDJLauJ 2007 Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21 607 615

37. TownsendCSchulteJThorneCDominguezKITookeyPA 2010 Antiretroviral therapy and preterm delivery-a pooled analysis of data from the United States and Europe. BJOG 117 1399 1410

38. PurdyJBGafniRIReynoldsJCZeichnerSHazraR 2008 Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 152 582 584

39. Soler-PalacinPMelendoSNoguera-JulianAFortunyCNavarroML 2011 Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS 25 171 176

40. JuddABoydKLStohrWDunnDButlerK 2010 Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 24 525 534

41. RiordanAJuddABoydKCliffDDoerholtK 2009 Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J 28 204 209

42. JonesSRestrepoDKasowitzAKorensteinDWallensteinS 2008 Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 19 913 918

43. PetersBIsohanniHTilletSalet 2010 Fracture risk in HIV and the need for guidelines: the Probono-1 trial [Abstract P099]. In: Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK; 7–11 November 2010

44. GrundBPengGGibertCLHoyJFIsakssonRL 2009 Continuous antiretroviral therapy decreases bone mineral density. AIDS 23 1519 1529

45. BonjochAFiguerasMEstanyCPerez-AlvarezNRosalesJ 2010 High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24 2827 2833

46. StellbrinkHJOrkinCArribasJRCompstonJGerstoftJ 2010 Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51 963 972

47. GafniRIHazraRReynoldsJCMaldarelliFTullioAN 2006 Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 118 e711 e718

48. ViganoAZuccottiGVPuzzovioMPivettiVZamproniI 2010 Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. Antivir Ther 15 1053 1058

49. NurutdinovaDOnenNFHayesEMondyKOvertonET 2008 Adverse effects of tenofovir use in HIV-infected pregnant women and their infants. Ann Pharmacother 42 1581 1585

50. SiberryGKWilliamsPLMendezHSeageGR3rdJacobsonDL 2012 Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS In press

51. Perinatal HIV Guidelines Working Group 2010 Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf. Accessed 20 January 2011

52. PowisKMSmeatonLOgwuALockmanSDryden-PetersonS 2011 Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana. J Acquir Immune Defic Syndr 56 131 138

53. World Health Organization 2006 Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2006 version) Geneva WHO

54. KagaayiJGrayRHBrahmbhattHKigoziGNalugodaF 2008 Survival of infants born to HIV-positive mothers, by feeding modality, in Rakai, Uganda. PLoS One 3 e3877 doi:10.1371/journal.pone.0003877

55. KuhnLSinkalaMSemrauKKankasaCKasondeP 2010 Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis 50 437 444

56. CreekTLKimALuLBowenAMasungeJ 2006 Hospitalization and mortality among primarily nonbreastfed children during a large outbreak of diarrhea and malnutrition in Botswana, 2006. J Acquir Immune Defic Syndr 53 14 19

57. World Health Organization 2010 Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access. Recommendations for a public health approach (2010 version) Geneva WHO

58. RajaratnamJKMarcusJRFlaxmanADWangHLevin-RectorA 2010 Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 375 1988 2008

59. GrayRHLiXKigoziGSerwaddaDBrahmbhattH 2005 Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 366 1182 1188

60. MoodleyDEsterhuizenTMPatherTChettyVNgalekaL 2009 High HIV incidence during pregnancy: compelling reason for repeat HIV testing. AIDS 23 1255 1259